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Abstract
Background & Aim: The aim was to extract factors from virologic and biochemical profiles at baseline and 24
weeks of treatment to predict HBeAg seroconversion in patients treated with ETV.
Methods: HBeAg positive chronic hepatitis B patients receiving ETV naïve-treatment were enrolled. HBV DNA, ALT,
and serological markers were prospectively monitored every 6 months for 240 weeks. The cumulative rates of virologic
response (VR), biochemical response (BR), and HBeAg seroconversion were determined, and potential predictors for
HBeAg seroconversion were identified through uni/multivariate analysis.
Result: Two hundred twenty nine patients were eligible for this study. The cumulative rates of VR, BR, and HBeAg
seroconversion at 240 weeks were 88.4 %, 100 %, and 36.7 %, respectively. Multivariate analysis showed that HBV
DNA (OR, 2.8, p = 0.003), ALT (OR, 2.6, p = 0.005) at baseline, undetectable HBV DNA within 24 weeks (OR = 3.2,
p < 0.001), and body mass index (BMI) ≥24kg/m2 (OR = 0.038, p = 0.013) were associated with HBeAg seroconversion.
A prediction model for probability of HBeAg seroconversion was constructed. Patients can be classified into high
(>40 %), intermediate (20–40 %), or low (≤20 %) groups based on the calculated probability of HBeAg seroconversion.
The cumulative rates of HBeAg seroconversion were different among the three groups (p < 0.001). About 58 % patients
in the high probability group achieved HBeAg seroconversion while almost 90 % patients within the low group remained
HBeAg positive.
Conclusion: A combination of HBV DNA, ALT and BMI values at baseline, and undetectable HBV DNA level within 24
weeks can predict HBeAg seroconversion. Both viral and metabolic factors likely determine HBeAg status with ETV
treatment.
Trial registration: CTR20132358
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Background
Chronic hepatitis B virus (HBV) infection currently af-
fects approximately 350–400 million people worldwide
[1]. It is well established that patients with high serum
HBV DNA levels are associated with worse prognosis
than those with low or undetectable HBV DNA [2].
Therefore, a major goal of clinical management of chronic
HBV infection is to prevent progression of the liver injury
and inflammation through sustained suppression of HBV
replication [3–5].
Currently, treatment mainly relies on long term use of
nucleos(t)ide analogues (NAs). NAs, especially new gener-
ation NAs including entecavir (ETV) can significantly in-
hibit viral replication to undetectable level in more than
80 % of treated patients, and normalize ALT in almost all
of them following long term therapy [6]. However, HBeAg
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seroconversion facilitated by ETV treatment remains low
with variable frequencies [7, 8].
HBeAg seroconversion is a critical event in natural
course of chronic HBV infection and during the antiviral
treatment [9]. It coincides with naturally reduced replica-
tion or sustained suppression of viral replication by antivi-
rals, and is linked with reduced risk for progression of liver
injury [10]. Patients who have successfully experienced this
switch usually become so-called inactive HBsAg carrier
who shows low serum HBV DNA and normal ALT. Im-
portantly, HBeAg seroconversion is accompanied by sig-
nificantly reduced HBV covalently closed circular DNA
(cccDNA) level in the liver [11]. Reduced cccDNA level
signals a better prospect for maintaining low level of HBV
replication [12]. If patients stay at HBeAg positive phase,
even though the liver inflammation has been brought
under control, they may face a higher risk for quick res-
toration of high level of HBV replication because of
relatively high intrahepatic cccDNA level once the anti-
viral therapy ceased [13]. Therefore, HBeAg serocon-
version is an important endpoint achieving a better
outcome of antiviral therapy.
So far, several baseline and on-treatment predictors for
HBeAg seroconversion have been suggested in the litera-
ture. Medium range of HBV DNA, higher ALT level, and
lower serum HBsAg level are considered baseline predic-
tors [14–16] for HBeAg seroconversion [17, 18]. In
addition to viral factors, we reasoned that NAs mediated
inhibition takes place within infected cells and efficient ac-
cess to viral replication site in each of infected cells by the
drug is essential for efficient inhibition function. Such ac-
cess could be impeded if there is excessive accumulation
of biologic molecules that clog intracellular traffic in hepa-
tocytes. It is well-known that hepatic steatosis is increas-
ingly prevalent. For instance, about 30 % of CHB patients
concur with hepatic steatosis [19]. We hypothesized that
metabolic factors can impact antiviral response and
HBeAg seroconversion.
The aim of this study was to evaluate efficacy leading to
HBeAg seroconversion associated with long term ETV
treatment and to build a model with the combined viral
and metabolic factors and to assess predictive utility of the
model for predicting HBeAg seroconversion.
Results
Study population
Of enrolled 270 CHB patients with HBeAg positive,
Forty-one patients, 14 (5.2 %) showed nonresponse at
week 48 and they discontinued the ETV therapy, and 27
(10.0 %) had unavailable serum HBV DNA data at week
24 or 48, were excluded (Fig. 1). A total of 229 patients
were eligible for this study. Table 1 showed the baseline
characteristics of study patients. Mean age was 30.7 ± 7.6
years old. There were 177 (77 %) male patients and 23
(10.0 %) patients had cirrhosis. The median baseline
serum ALT level was 134.2 ± 93.5 IU/L and HBV DNA
level was 8.1 ± 1.3 log10copies/ml. The median treatment
duration was 212 weeks (range 84 to 337 weeks). During
the follow-up visits, 77 patients who reached the primary
endpoint with HBeAg seroconversion exited from the
treatment, and additional 45 patients ceased treatment.
Reasons for discontinuation included lack of efficacy
and the financial ability to cover high cost (16, 7.0 %),
loss to follow-up (17, 7.4 %), pregnancy (3, 1.3 %), with-
drawal of consent (2, 0.9 %), noncompliance (5, 2.2 %),
and adverse event (2, 0.9 %). Finally, 107 patients con-
tinued therapy throughout the study.
Antiviral efficacy of long term ETV therapy
The cumulative probability of undetectable HBV DNA
increased from 46.1 % at 48 weeks to 88.4 % at 240
weeks (Fig. 2). Proportion of ALT normalization was in-
crementally expanded as well. Up to 240 weeks, nearly
all people had reached normal range (Fig. 3). During the
study, 77 patients underwent HBeAg seroconversion.
Two patients achieved HBsAg loss. The cumulative rates
of HBeAg seroconversion were 11.8 %, 20.6 %, 25.7 %,
30.4 %, and 36.7 % over the duration of 1, 2, 3, 4, and 5
years, respectively, as displayed by Fig. 4. Seven patients
experienced virological breakthrough; 3 of them were ac-
companied by biochemical breakthrough. Six patients
still had detectable HBV DNA at the last visit. All of
them showed good compliance. The patients with viro-
logic breakthrough or detectable HBV DNA were tested
for the genotypic mutations. Two patients were docu-
mented to confer resistance to ETV; the amino acid sub-
stitution loci were + L180M + T184G + S202I + M204V
and M204V + L180M + S202G + V173L, respectively.
The two received an ADV- add-on regimen. Among the
patients without drug resistance, 8 patients switched to
ETV plus ADV combination therapy, and three increased
ETV dosage to 1mg per day.
Comparison of pretreatment and on-treatment factors
between patients with and without HBeAg seroconversion
Demographic and clinical data at baseline and on-
treatment in patients with and without HBeAg serocon-
version were summarized in Table 2. Mean age (≤or > 40
years) and gender ratio were well-balanced between two
groups. The baseline HBV DNA level was stratified to
three subgroups: 1. ≤7; 2. 7–9; and 3. ≥9 log10 copies/ml.
A majority of patients with HBV DNA at 7–9 log10 cop-
ies/ml showed HBeAg seroconversion while HBeAg sero-
conversion in patients with high HBV DNA load >9 log10
copies/ml occurred much less frequent and the majority
remained HBeAg positive. The difference was statistically
significant (P = 0.001). All patients were also divided to
two groups based on the baseline ALT level at 200IU/L.
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The percentage of patients with ALT ≥200 IU/L with
HBeAg seroconverted was nearly two times higher than
that of the non-seroconverted (P = 0.008). Interestingly,
patients with HBeAg seroconversion had lower baseline
BMI (categorized as normal BMI <24kg/m2, overweight
BMI ≥24 kg/m2 based on the World Health Organization
guidelines for adult Chinese population [20]) than that of
the non-seroconverted group (mean, 21.6 ± 2.3 vs. 22.6 ±
2.5, p = 0.004), and the percentage of patients with BMI <
24kg/m2 in the former group was significant higher than
that of the latter group (90 % vs.67 %, p < 0.007).
Clear differences in reduction of HBV DNA to un-
detectable level within 24 weeks from baseline (P =
0.014), and reduction of ALT to normal range within
12 weeks (P = 0.002) or 24 weeks (P = 0.001) from
baseline were observed between two groups. However,
if each parameter was used independently to predict
the probability of HBeAg seroconversion, the corre-
sponding AUS value was low (ranging from 0.5 to 0.7),
and the positive predictive value was not promising.
There was no correlation between BMI and HBV
DNA or ALT at the baseline (P = 0.098 and 0.071, re-
spectively). Notably, BMI was negatively correlated
with the decline of HBV DNA level within 24 weeks,
Table 1 Baseline characteristics of enrolled patients
Characteristics HBeAg positive
(n = 229)
Age,yr 30.7 ± 7.6
Male,(%) 177(77 %)
BMI (kg/m2) 22.3 ± 2.4
Cirrhosis 23(10 %)
Median treatment duration 212(84–337)
Median HBV DNA(log10copies/ml) 8.1 ± 1.3
Serum ALT (IU/L) 134.2 ± 93.5
Serum AST (IU/L) 81.2 ± 54.0
Serum ALP (IU/L) 103.1 ± 32.6
Total bilirubin (mg/dL) 0.9 ± 0.3
Serum albumin (g/L) 45.2 ± 3.5
Platelet count (10^9/L) 153.1 ± 80.0
Serum creatinine (mg/dl) 0.9 ± 0.2
WBC (10^9/L) 5.4 ± 1.4
Fig. 1 The flow chart showing enrollment and exits of patients during the course of treatment
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and the correlation coefficient was −0.7; no correlation
between BMI and other factors was found.
Predictive factors associated with HBeAg seroconversion
To avoid confounding effects, we adjusted the on-
treatment factors, and included the following in the re-
gression analysis: the time of undetectable HBV DNA
(≤24 weeks, between 24 and 48 weeks, >48 weeks), and
the time of the normalization of ALT(≤12weeks, be-
tween 12 and 24 weeks, >24weeks). Our univariate
analysis showed that BMI, HBV DNA and ALT levels at
baseline, the time of VR, and the time of the
normalization of ALT were the factors associated with
HBeAg seroconversion (Table 3). However, the multi-
variate Cox proportional hazards analysis showed that
BMI with more than 24kg/m2 (odds ratio [OR], 0.038;
95 % confidence interval [CI], 0.2 to 0.8; p = 0.013),
baseline HBV DNA level <9 log10copies/ml (OR, 2.8; 95
% CI, 1.4 to 5.6; p = 0.003), baseline ALT level ≥ 200
IU/L (OR, 2.5; 95 % CI, 1.3 to 4.8; p = 0.005), and
undetectable serum HBV DNA within 24 (OR, 3.2; 95
% CI, 1.9 to 5.5; p < 0.001) were significantly important
in predicting HBeAg seroconversion. Differed from
other variables, BMI ≥24 kg/m2 was negatively related
to HBeAg seroconversion.
A model to predict HBeAg Seroconversion
A model for predicting HBeAg seroconversion was con-
structed using regression coefficient for each covariate ob-
tained through multivariable logistic regression analysis.
The Hosmer-Lemeshow goodness-of-fit test was good
(P = 0.915). The regression formula for predictive prob-
ability of HBeAg seroconversion (P) is:
P = eA/(eA + 1), and A = −1.549 + 0.792(if baseline
ALT level ≥ 200 IU/L IU/L)-0.309 (if ALT level (<200) +
1.290 (if baseline HBV DNA level ≤ 9 log10 copies/
ml)-0.403(if HBV DNA level >9) -1.388 (if BMI ≥24kg/
m2) + 1.188 (if undetectable HBV DNA within 24
weeks)-0.364 (if undetectable HBV DNA within 48 week).
Fig. 3 The cumulative probability of ALT normalization through the observation duration by Kaplan–Meier analysis
Fig. 2 The cumulative probability of undetectable HBV DNA through the observation duration by Kaplan–Meier analysis
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Fig. 4 The cumulative probability of HBeAg seroconversion by Kaplan–Meier analysis
Table 2 Comparison of clinical features between patients with and without seroconversion
Characteristics Seroconversion Non-seroconversion p-value
(n = 77) (n = 152)
Age yr
Age ≤ 40 67 (34 %) 132 (66 %) 0.971
Age > 40 10 (33 %) 20 (67 %)
Gender
Female 19 (36 %) 33 (64 %) 0.613
Male 58 (33 %) 119 (67 %)
BMI (kg/m2)
<24 69(40 %) 102(60 %) <0.001
≥24 8(14 %) 50(86 %)
HBV DNA level(log10copies/ml)
HBV DAN < 7 10(21 %) 38(79 %) 0.001
7 ≤ HBV DNA < 9 56(44 %) 71(56 %)
HBV DNA ≥ 9 11(20 %) 43(80 %)
Baseline ALT level (IU/L)
ALT ≥ 200 25(49 %) 26(51 %) 0.008
ALT < 200 52 (29 %) 126 (71 %)
Undetectable HBV DNA within 24 weeks 32 (54 %) 27 (46 %) <0.001
Undetectable HBV DNA within 48 weeks 44 (40 %) 65 (60 %) 0.062
Normalization ALT within 12 weeks 12 (50 %) 12 (50 %) 0.232
Normalization ALT within 24 weeks 25 (56 %) 20 (44 %) 0.001
Reduction HBV DNA at 24 weeks from baseline 4.7 ± 1.2 4.0 ± 1.4 <0.001
Reduction HBV DNA at 48 weeks from baseline 5.0 ± 1.0 4.9 ± 1.3 0.609
Reduction ALT at 12 weeks from baseline 106.0 ± 109.0 61.1 ± 102.3 0.002
Reduction ALT at 24 weeks from baseline 123.6 ± 106.7 77.0 ± 91.1 0.001
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The probability for HBeAg seroconversion in each of
all patients was computed and determined, and then two
cut-off values were designated (see the justification for
each value selection in Discussion). According to the
calculated individual probability and the cut-off values,
patients were categorized to high (>40 %), intermediate
(20 %-40 %), or low (≤20 %) HBeAg seroconversion
group. Approximately 58 % of patients in the high prob-
ability group achieved HBeAg seroconversion compared
with 11 % and 31 % in the low and intermediate prob-
ability groups, respectively (Fig. 5). The seroconversion fre-
quencies were significantly different (p < 0.001). The
cumulative rates of HBeAg seroconversion in the high
response group were significant greater than another
two groups at the same time points. The cumulative
rate increased slowly and remained nearly unchanged
throughout the study period in the low probability
group (Fig. 6, log rank test p < 0.001).
Table 3 Analysis of baseline factors for HBeAg seroconversion by multivariate cox proportional hazard analysis
Baseline characteristics Univariate Multivariate
P Odd ritio 95 % CI P
Age, yr 0.438
Gender (male/female) 0.896
BMI (≥24 kg/m2) <0.001 0.4 0.2–0.8 0.013
Baseline ALT (IU/L) 0.004
ALT < 80 0.003 1 1
80 ≤ ALT < 200 0.995 1.1 0.6–2.0 0.83
ALT ≥ 200 0.002 2.5 1.3–4.8 0.005
Baseline HBV DNA(log10copies/ml) <0.01
HBV DAN < 7 <0.001 1 1
7 ≤ HBV DNA < 9 <0.001 2.8 1.4–5.6 0.003
HBV DNA ≥ 9 <0.001 0.8 0.3–2.0 0.773
Time of undetectable HBV DNA <0.01
≤24 weeks <0.001 3.2 1.9–5.5 <0.001
24 < HBV DNA ≤ 48 weeks <0.001 1.3 0.6–2.9 0.485
>48 weeks 0.385 1 1
Time of Normalization ALT
≤12 weeks 0.346
12 < ALT ≤ 24 weeks 0.018
>24 weeks 0.007 1 1
Fig. 5 Distribution of patients with HBeAg seroconversion among three groups stratified by probability calculated by the model
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Discussion
ETV is one of new generation NAs that have demon-
strated more potent inhibition of HBV DNA replication
than earlier ones. However, HBeAg seroconversion facili-
tated by ETV therapy remains relative low, for instance
only about 20 % of HBeAg positive patients achieved
HBeAg seroconversion after 48 weeks ETV therapy [21].
Factors associated with HBeAg seroconversion are not
well understood and it is difficult to predict HBeAg
seroconversion. But an ability for physicians to accur-
ately predict HBeAg seroconversion is needed to im-
prove clinical management of patients with chronic
hepatitis B. We investigated the antiviral efficacy of long
term ETV treatment of HBeAg positive chronic HBV in-
fected patients in this study. We found that ETV was a
highly potent antiviral agent. The cumulative rates of VR
and BR were comparable to those observed in previous
studies [22, 23]. We focused on identifying and testing
both viral and metabolic factors, which were extracted
from virologic and biochemical profiles at baseline and
within 24 weeks of treatment, for impacting HBeAg sero-
conversion. We found that BMI values were inversely re-
lated to changes in HBeAg status, and serum HBV DNA,
ALT values at baseline, as well undetectable HBV DNA
level within 24 weeks after the treatment were positively
related to HBeAg seroconversion. We constructed a model
that incorporated both viral and metabolic factors, and can
assign each patient with low, or medium or high probabil-
ity for serum HBeAg seroconversion. The cumulative rate
of HBeAg seroconversion at the end of 5 year treatment in
this study was lower than previous results [7, 24]. Possible
factors included that the dominant HBV strain in China is
genotype C, which is associated with lower rates of sero-
conversion than genotypes A or B [25]. Additionally, the
subjects who discontinued therapy were considered as fail-
ure that may underestimate the actual conversion rates.
An interesting factor identified by this study was an
indicator for abnormal metabolism: BMI (≥24kg/m2)
that was inversely associated with HBeAg seroconver-
sion. In agreement with this finding, we noted that
patients with higher BMI showed poorer virologic re-
sponse at early phrase (before 24 weeks). The poorer
virologic response suggests an inefficient inhibition of
viral replication, which may have contributed to delay-
ing HBeAg seroconversion. Some studies previously in-
dicated that BMI was an independent factor for hepatic
steatosis [26]. And hepatic steatosis was documented to
have a negative effect on the therapy efficacy, and even
it could result in ETV treatment failure [27]. Although
conclusive data on the effect of steatosis remains to be
established, a hypothesis is that not only viral factors,
but also metabolic factors like hepatic steatosis in CHB
patients are likely determining antiviral response in-
cluding HBeAg seroconversion. It is possible that the
contact between the HBV replication site and drug
within hepatocytes could be separated or blocked by ac-
cumulated fat [28]. As a result of such separation, the
drug may not effectively access to the viral replicating
site . This difficulty may be further impeded by dimin-
ished activity of hepatic cytochromes in steatosis hepato-
cytes [19]. Additionally, patients with hepatitis C that is
often marked by hepatic steatosis, are frequently accom-
panied by obesity and insulin resistance that may result in
dysfunction of cellular immunesystem [29]. Currently
obesity is increasingly spreading among various popula-
tions even in developing countries, and lipid metabolism
disorders such as hepatic steatosis occur more frequently
among general population, It is not surprising that CHB
patients can have hepatic steatosis and the prevalence for
such co-existence is up to 30.5 % [30]. Further studies
would be expected to focus on impacts of steatosis on
antiviral response at molecular level, and it may call for
Fig. 6 The cumulative probability of HBeAg seroconversion determined by the model
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new antiviral strategy for CHB patients with hepatic stea-
tosis or higher BMI.
This study also revealed that undetectable HBV DNA
within 24 weeks was the most important independent pre-
dictive factor for HBeAg seroconversion as its regression
coefficient was the highest among the four predictive fac-
tors. The result is in line with previous study [31]. Further-
more,the finding could be explained by the suggestion that
antiviral therapy with NAs can induce partial restoration of
immune responses [32], which are necessary for the dur-
able host-mediated control of infection. And it is thought
that rapid HBV DNA suppression may reflect this restor-
ation of immune response in the host by stimulating the T-
cell response and enhancing the probability of reducing the
HBeAg expression in the long term [33]. Therefore, HBV
DNA level at 24 weeks is an essential marker to monitor
HBeAg seroconversion in ETV treatment.
Apart from two factors mentioned above, relatively lower
HBV DNA levels (<107 copies/ml) at baseline were inde-
pendently associated with a stepwise increasing rate for the
HBeAg seroconversion. A same finding was observed in
previous studies [34]. Consistently, HBeAg seroconversion
in patients treated with LDT can be predicted by baseline
HBV DNA and ALT levels [35]. ALT reflects liver injury/
inflammation that could be triggered by the host immune
response. Our result that a higher baseline ALT level (≥200
IU/L) was related to HBeAg seroconversion was similar to
previous study by Tseng TC et al. [36]. Therefore, levels of
baseline ALT can be considered as a critical factor for pre-
dicting antiviral response including HBeAg seroconversion
before tailoring antiviral treatment.
After identifying these four independent predictive fac-
tors, we constructed a formula that could assist physicians
to predict approximately probability of HBeAg serocon-
version for individual patients. As tested by this study,
nearly 60 % of patients in the high probability group
achieved HBeAg seroconversion. Interestingly extended
study only resulted in a moderate increase in HBeAg sero-
conversion in the intermediate group. For those patients
close monitor of HBV DNA before 48 weeks would be im-
portant to decide whether they were having an optimal
treatment. In comparison, the cumulative rate of HBeAg
seroconversion showed no additional increase in the low
response group over time, suggesting that those patients
may retain HBeAg for a long period despite long term
ETV therapy. Therefore, patients with probability more
than 40 % could have a great chance to achieve HBeAg
seroconversion. Additionally, patients with BMI (<24Kg/
m2), plus lower HBV DNA (>7 < 9log10copies/ml) and
higher ALT (≥200IU/L) and HBV DNA undetectable be-
fore 24 weeks had a greater probability to develop serocon-
version. The remaining patients were less likely for
HBeAg seroconversion. Particularly, patients with BMI
(≥24Kg/m2), high HBV DNA (>9 log10copies/ml) levels
at baseline and detectable HBV DNA at 48 weeks were
candidates for discontinued ETV treatment.
The cut-off values for the stratification of individual
probability were decided by considering the natural his-
tory of CHB and recognized efficacy of ETV long-term
treatment. According to prior studies, the annual inci-
dence of spontaneous HBeAg seroconversion is about
2–15 %, and thus 20 % was chosen as the lower cut-off
value to exclude spontaneous HBeAg seroconversion [37].
The probability of HBeAg seroconversion under ETV five
years’ therapy is approximately 40 % or more [8], thus this
value was selected as the upper cut-off line.
However, the predictive factors included in this study are
not exhaustive, as some known risk factors were omitted,
instead of using several easily available parameters. The
hepatic steatosis was not included because ultrasound
based detection of steatosis shows lower sensitivity and
specificity, which largely depends on the operators’ skill.
Recently, quantitative HBeAg and HBsAg levels have
been shown to have predictive value for HBeAg sero-
conversion in ETV-treated patients [18]. However, the
accurate HBeAg and HBsAg values were not available
in this study, so those markers could not be assessed.
Likewise, core promoter or pre-core mutations might
represent additional factors for loss of HBeAg expres-
sion [38], but they are not routinely monitored in clinic.
Therefore, the predictive power of this model for HBeAg
seroconversion can be augmented if all predictive factors
are incorporated.
This study is associated with a few limitations. First, the
sample size was relatively small and the age range of pa-
tients was narrow because the HBeAg positive patients
tend to be younger. The conclusions should be confirmed
by future studies with large cohorts from multicenter. Sec-
ond, all of our patients were Asians; therefore, it should
be cautious to see if results can be extrapolated to other
ethnic or genotypic patients. Finally, a lack of validated
group to verify the prospective model is one challenge for
all similar studies.
Conclusions
Long-term ETV treatment was effective. Baseline HBV
DNA and ALT levels and undetectable HBV DNA within
24 weeks were positive markers while BMI value was a
negative factor for HBeAg seroconversion. Our model can
separate treated HBeAg positive patients into three cat-
egories with differentiated probabilities. We tested and
found that HBeAg seroconversion can be as high as 60 %
in high probability group. The model may have potential
to be incorporated into a clinical rate-prediction instru-
ment that could improve the antiviral efficacy through ap-
propriate choice at baseline, which could result in timely
adjustment of regimen for individual patients. However,
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the observation should be confirmed in a prospective and
larger numbers of patients study.
Materials and methods
Study population
This was a prospective cohort study that consecutively en-
rolled patients who entered the multicenter trial studies
(CTR20132358) in the Department of Infectious Diseases,
the Second Affiliated Hospital of Chongqing Medical
University between March 2006 and April 2013. To ex-
plore the potential predictors for HBeAg seroconver-
sion, patients recruited in the study were a component
of the full study protocol. Patients were included into
this study if they were hepatitis B surface antigen (HBsAg)
and HBeAg positive for at least 6 months, baseline HBV
DNA level greater than 105copies/mL and ALT 1.3 times
more than the upper limit of normal (ULN). All of patients
were older than age 16. All of them were nucleoside-naïve
and received ETV 0.5mg/day for at least 48 weeks. Patients
with antibodies positive against hepatitis C or D virus, or
human immunodeficiency virus, or those with decompen-
satory liver cirrhosis (ascites, jaundice, gastrointestinal
bleeding, or encephalopathy) and a history of liver trans-
plantation and HCC were excluded.
Study design
The baseline characteristics and laboratory data of
enrolled patients were recorded by chart review.
Clinical evaluation was performed to record some
general characteristics, such as age, gender, BMI,
duration of treatment. Laboratory variables included
serologic markers of HBV, serum HBV DNA levels
and serum biochemistry data such as levels of
ALT,aspartate aminotransferase,alkaline phosphatase,
total bilirubin,serum albumin, serum creatinine, and
blood routine examination. Patients were followed
every 6 months to assess HBV DNA and ALT levels,
drug tolerability and compliance. Patients with
HBeAg seroconversion were followed for at least 24
weeks. Genotypic resistance was analyzed in patients
with virologic breakthrough or relapse, and new anti-
viral regimens were given at the discretion of investi-
gators, which was omitted in the H20080798.
Patients who were lost during the follow-up or con-
tinued ETV therapy without seroconversion for the
entire study period were considered as HBeAg sero-
conversion failure.
Assay methods
HBeAg and anti-HBe were detected by AxSYM micropar-
ticle enzyme immunoassay (Abbott Laboratories, Abbott
Park, IL, USA). Serum HBV DNA was quantified by real-
time polymerase chain reaction (PCR) assay using the
COBAS Taq-Man HBV quantitative test (Roche Molecular
Systems Inc., Branchburg, NJ, USA), which has a low limit
of quantification of 1000 copies/ml. Biochemical data were
measured using an auto-analyzer (Roche Analytics; Roche
Professional Diagnostics, Penzberg, Germany). The upper
limit of normal for serum ALT level is 40 IU/L. Genotypic
resistance was performed by restriction fragment mass
polymorphism (RFMP) analysis.
Evaluation of treatment efficacy and definitions
The primary endpoint was the HBeAg seroconversion, de-
fined as undetectable HBeAg and detection of HBe anti-
body followed beyond 24 weeks. The second endpoints
used the BR defined as ALT returned to the normal range,
and the undetectable HBV DNA, defined as HBV DNA
decreased to less than 1000 copies/mL. Virologic break-
through was defined as an increase in HBV DNA level
of >1*log10copies/ml compared with the nadir. Genotypic
resistance was defined as the appearance of viral mutations
bearing amino acid substitutions in the reverse transcript-
ase region. Each cumulative probability for respective un-
detectable HBV DNA, normalized ALT and HBeAg, was
used to determine ETV antiviral efficacy.
Data analysis
HBV DNA levels were logarithmically transformed.
Continuous variables were expressed as mean ± SD.
Categorical data were analyzed using the chi-square
test. The correlation analysis was conducted by Pearson
coefficient. Cumulative probability was evaluated by
Kaplan-Meier analysis. Cox regression analysis was
used to explore the factors with serologic response. To
assess predictive accuracy of related factor, receiver op-
erating characteristic (ROC) curves were constructed
and the area under the ROC curve (AUC) was calcu-
lated. Multivariable logistic regression analysis was
used to estimate the β regression coefficient and then
to construct a multivariable linear model. The regres-
sion analysis was performed with stepwise selection,
using a P value greater than 0.05 for removal and less
than 0.1 for entering. All statistical tests were two-
sided, and P < 0.05 was considered statistically signifi-
cant. IBM SPSS statistics version 20 (IBM Corporation,
Armonk, NY) was used for statistical analysis.
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